Every article, report, and earnings note where MCK appears.
McKesson Corporation (MCK) rose after beating EPS and revenue estimates, but the real story goes beyond the headline. This deep-dive examines segment drivers, guidance, cash flow, shareholder returns, and the Medical-Surgical separation to show why the quarter strengthened the forward outlook.
McKesson posted double-digit fiscal 2026 growth, led by oncology, multispecialty, and prescription technology services. The stock earns a Buy, but valuation and a leveraged balance sheet keep the upside more measured.
McKesson Corporation (MCK) rises 7.2% after reporting earnings beats, as investors react to stronger-than-expected results and improved outlook for the healthcare distributor.
A seven-stock healthcare countdown spans telehealth, devices, life-science tools, diagnostics, distribution, and managed care, with HIMS, BDX, TMO, DHR, and ABT in focus.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate MCK ReportCancel anytime